RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On February 17, 2017, Robert N. Weingarten informed the Board of
Directors of RespireRx Pharmaceuticals Inc. (the Company) that he
had decided to resign as a director, Vice President and Chief
Financial Officer of the Company and its subsidiary, as of that
date. Mr. Weingarten indicated that his resignation was for
personal reasons, and the Company does not believe the
resignation was the result of any disagreement with the Company
on any matter relating to the Companys operations, policies or
practices. The substance of the email that Mr. Weingarten sent
regarding his resignation is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
The Board of Directors, acting by written consent on February 22,
2017, appointed Jeff E. Margolis, the Companys Vice president,
Treasurer and Secretary, to act as the Companys interim Chief
Financial Officer. As an existing officer and director of the
Company, information regarding Mr. Margolis is provided in the
Companys most recent Annual Report on Form 10-K, filed on March
29, 2016, and that information is incorporated herein by
reference.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits.
A list of exhibits that are furnished and filed as part of this
report is set forth in the Exhibit Index, which is presented
elsewhere in this document, and is incorporated herein by
reference.
About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)
RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea. RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Recent Trading Information
RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) closed its last trading session 00.00 at 3.90 with 115 shares trading hands.
